NewAmsterdam Pharma (NAMS) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $41
Moomoo NewsMar 3 09:33 ET · Ratings
Express News | NewAmsterdam Pharma Company NV : Guggenheim Raises Target Price to $41 From $35
ReutersMar 3 06:41 ET
NewAmsterdam Pharma Files $500M Mixed Securities Shelf
TipRanksFeb 28 17:10 ET
NewAmsterdam Pharma's 2024 Financial Results and Clinical Progress
TipRanksFeb 28 00:12 ET
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $38
Moomoo NewsFeb 27 21:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)
TipRanksFeb 27 21:30 ET · Ratings

Comments

10xStockPicks

Feb 21 07:57

Esperion Therapeutics On The Verge Of Being Acquired, Upside Could Be Over 500% In The Near Future

$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...

7

5

2

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

11

2

4

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

+4

6

9

1

103848509

Dec 10, 2024 07:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly

Jaguar8

Nov 20, 2024 08:16

NEWS

$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...

NAMS NewAmsterdam Pharma

Trade Overview

Capital Trend

News

Comments

Trending Stocks